SCM
APLS

Silverarc Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Silverarc Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,000
Closed -$599K – 80
2023
Q4 		$599K Buy
+10,000
New +$507K 0.18% 62
2022
Q3 		– Sell
-129,795
Closed -$5.87M – 82
2022
Q2 		$5.87M Buy
129,795
+24,427
+23% +$1.11M 2.75% 19
2022
Q1 		$5.35K Buy
+105,368
New +$4.65M 2.54% 11
2021
Q3 		– Sell
-7,009
Closed -$443 – 85
2021
Q2 		$443 Buy
+7,009
New +$362K 0.22% 84

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return